肝星状细胞
衰老
调节器
白血病抑制因子受体
癌症研究
车站3
纤维化
基因敲除
肝纤维化
生物
肝纤维化
下调和上调
受体
信号转导
细胞衰老
细胞生物学
白血病抑制因子
免疫学
医学
细胞
白血病
肝损伤
作者
Bingbing Zhao,Zhengwei Zhang,Xiaoxue Li,Shiyun Dong,Xin Zhong,Zhitao Li,Ye Jin,Yun Bai,Can Wei
标识
DOI:10.1007/s10565-026-10268-y
摘要
Liver fibrosis represents a major unmet clinical challenge, and induction of hepatic stellate cell (HSCs) senescence has emerged as a promising therapeutic strategy to halt or reverse fibrotic progression. PPARγ is a key regulator of HSCs quiescence; however, the downstream molecular mechanisms mediating its pro-senescence effects remain poorly defined. Here, we demonstrate that PPARγ expression is markedly reduced in a CCl₄-induced mouse liver fibrosis model and that its restoration drives HSC inactivation and senescence. Through integrated bioinformatics analysis and functional validation in PPARγ-overexpressing HSC-T6 cells, we identified leukemia inhibitory factor receptor (LIFR) as a direct transcriptional target of PPARγ. Mechanistically, PPARγ upregulates LIFR to suppress STAT3 phosphorylation, thereby downregulating fibrosis markers CO Ⅰ and α-SMA, elevating P21 and γ-H2A.X, and reducing CCND1. Crucially, LIFR knockdown abolished all PPARγ-mediated effects, confirming its indispensable role in this axis. Furthermore, combined treatment with the STAT3 inhibitor WP1066 synergistically enhanced PPARγ-driven HSC senescence in a LIFR-dependent manner. These findings establish a PPARγ-LIFR-STAT3 signaling cascade as a critical regulator of HSCs fate, and suggest that pharmacological activation of this axis represents a tractable approach for fibrosis resolution.
科研通智能强力驱动
Strongly Powered by AbleSci AI